PT2004646T - Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação - Google Patents

Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação

Info

Publication number
PT2004646T
PT2004646T PT77746402T PT07774640T PT2004646T PT 2004646 T PT2004646 T PT 2004646T PT 77746402 T PT77746402 T PT 77746402T PT 07774640 T PT07774640 T PT 07774640T PT 2004646 T PT2004646 T PT 2004646T
Authority
PT
Portugal
Prior art keywords
phenyl
decan
diaza
spiro
trifluoromethyl
Prior art date
Application number
PT77746402T
Other languages
English (en)
Inventor
Shih Neng-Yang
Paliwal Sunil
Mergelsberg Ingrid
Hu Mengwei
Guenter Frank
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38542035&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2004646(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of PT2004646T publication Critical patent/PT2004646T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT77746402T 2006-04-05 2007-04-04 Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação PT2004646T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78928006P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
PT2004646T true PT2004646T (pt) 2016-07-14

Family

ID=38542035

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77746402T PT2004646T (pt) 2006-04-05 2007-04-04 Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação

Country Status (16)

Country Link
US (5) US8178550B2 (pt)
EP (4) EP2662373A1 (pt)
JP (3) JP5352446B2 (pt)
CN (2) CN101437821B (pt)
AR (1) AR060353A1 (pt)
CA (1) CA2648604C (pt)
ES (1) ES2584838T3 (pt)
HU (2) HUE028908T2 (pt)
LT (1) LTPA2017031I1 (pt)
MX (1) MX2008012935A (pt)
PE (3) PE20142329A1 (pt)
PL (1) PL2004646T3 (pt)
PT (1) PT2004646T (pt)
SG (2) SG170838A1 (pt)
TW (1) TWI363058B (pt)
WO (1) WO2007117486A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US7563801B2 (en) 2006-04-05 2009-07-21 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
CN101437821B (zh) * 2006-04-05 2014-06-04 欧科生医股份有限公司 8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐酸盐及其制备方法
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
PE20081891A1 (es) * 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
MX2011002475A (es) 2008-09-05 2011-08-03 Opko Health Inc Procedimiento e intermediarios para la sintesis de compuestos de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-espiro[4.5]decan-2-ona.
RU2017145628A (ru) * 2009-08-14 2019-02-19 ОПКО Хельс, Инк. Композиции антагонистов нейрокинина-1 для внутривенного введения
CN105017251B (zh) * 2015-06-30 2018-06-29 齐鲁制药有限公司 一种nk-1受体拮抗剂的制备方法及其中间体
FR3047665B1 (fr) 2016-02-17 2020-12-11 Pf Medicament Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法
WO2021013981A1 (en) * 2019-07-25 2021-01-28 Intervet International B.V. Crystalline form of telmapitant or (5r,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
EP4125875A1 (en) 2020-04-03 2023-02-08 NeRRe Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
IL298589A (en) 2020-06-02 2023-01-01 Nerre Therapeutics Ltd Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis promoted by mechanical lung injury

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666856B1 (en) 1992-10-28 2000-01-05 MERCK SHARP & DOHME LTD. 4-arylmethyloxymethyl piperidines as tachykinin antagonists
EP0673367A1 (en) 1992-12-14 1995-09-27 MERCK SHARP & DOHME LTD. 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
EP0739336B1 (en) 1994-01-13 1998-08-26 MERCK SHARP & DOHME LTD. Gem-disubstituted azacyclic tachykinin antagonists
ATE207359T1 (de) 1995-08-28 2001-11-15 Schering Corp Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
CA2293836C (en) * 1997-07-02 2007-06-05 Louis Crocker Polymorphic form of a tachykinin receptor antagonist
IL157351A0 (en) 2001-02-12 2004-02-19 Teva Pharma New crystal forms of oxcarbazepine and processes for their preparation
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
EP1575962A1 (en) 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
GB0321256D0 (en) 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
AU2004308935A1 (en) 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
ES2327654T3 (es) 2004-04-07 2009-11-02 Schering Corporation Antagonista de nk1 de anillo condensado.
WO2006007540A2 (en) 2004-07-01 2006-01-19 Schering Corporation Piperidine derivatives as nk1 antagonists
AU2005304672B2 (en) 2004-11-09 2010-03-11 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level
CN101437821B (zh) 2006-04-05 2014-06-04 欧科生医股份有限公司 8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐酸盐及其制备方法
TW200806666A (en) 2006-04-05 2008-02-01 Schering Corp Salts of 8-[(1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
US7563801B2 (en) 2006-04-05 2009-07-21 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
BRPI0716026A2 (pt) 2006-08-07 2013-08-06 Stiefel Laboratories compostos antiféngicos cristalinos
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
MX2011002475A (es) 2008-09-05 2011-08-03 Opko Health Inc Procedimiento e intermediarios para la sintesis de compuestos de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-espiro[4.5]decan-2-ona.
RU2017145628A (ru) 2009-08-14 2019-02-19 ОПКО Хельс, Инк. Композиции антагонистов нейрокинина-1 для внутривенного введения

Also Published As

Publication number Publication date
US20190375751A1 (en) 2019-12-12
EP2662374A1 (en) 2013-11-13
PL2004646T3 (pl) 2016-12-30
JP2013032404A (ja) 2013-02-14
MX2008012935A (es) 2008-10-15
US20070244142A1 (en) 2007-10-18
PE20120545A1 (es) 2012-05-21
EP2676957A1 (en) 2013-12-25
CN101437821B (zh) 2014-06-04
JP5352446B2 (ja) 2013-11-27
CN101437821A (zh) 2009-05-20
JP5856944B2 (ja) 2016-02-10
EP2004646A2 (en) 2008-12-24
WO2007117486A3 (en) 2008-02-14
JP2009532472A (ja) 2009-09-10
JP2014240437A (ja) 2014-12-25
EP2004646B1 (en) 2016-06-08
JP6122411B2 (ja) 2017-04-26
CN102276606B (zh) 2013-06-12
US20100048601A1 (en) 2010-02-25
TWI363058B (en) 2012-05-01
EP2662373A1 (en) 2013-11-13
CA2648604A1 (en) 2007-10-18
US20150210693A1 (en) 2015-07-30
LTPA2017031I1 (lt) 2017-11-10
SG10201500027TA (en) 2015-02-27
TW200815439A (en) 2008-04-01
ES2584838T3 (es) 2016-09-29
US10196394B2 (en) 2019-02-05
SG170838A1 (en) 2011-05-30
PE20142329A1 (es) 2015-01-30
CA2648604C (en) 2016-05-24
AR060353A1 (es) 2008-06-11
HUE028908T2 (en) 2017-01-30
US8178550B2 (en) 2012-05-15
PE20071220A1 (es) 2007-12-14
US20130281477A1 (en) 2013-10-24
US8470842B2 (en) 2013-06-25
HUS1700037I1 (hu) 2017-11-28
WO2007117486A2 (en) 2007-10-18
CN102276606A (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
HUS1700037I1 (hu) A 8-[{1-(3,5-bisz-(trifluor-metil)-fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]dekan-2-on hidroklorid sója, és eljárás elõállítására
SG10201500028RA (en) Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
HRP20130536T1 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
EP1997820A4 (en) METHOD OF PREPARATION AND USE OF COMPOUNDS HAVING BIOCIDAL ACTION
IL205220A0 (en) 8 - [4 - (1 - AMINOCYCLOBUTYL)PHENYL]-9- PHENYL [1,2,4] TRIAZOLO [3,4-f]- 1,6 - NAPHTHYRIDINS AND THEIR USE FOR THE PREPARATION OF A MEDICAMENT FOR TREATING CANCER
PL2641651T3 (pl) Katalizowany filtr sadzy o zrównoważonym ciśnieniu
GB0403635D0 (en) Pyridinocarboxamides with improved activity as kinase inhibitors
EP1843805A4 (en) ANTIMICROBIAL NEEDLE COATING FOR ADVANCED INFUSION
EP1983831A4 (en) PHENYL AND PYRIDIL COMPOUNDS FOR INFLAMMATION AND IMMUNOUS USE
HK1098700A1 (en) Use of drug combinations for treating insulin resistance
IL182459A0 (en) Compounds for nonsense suppression, and methods for their use
EP1919550A4 (en) TWO-CHANNEL PUMP CARTRIDGE AND DIALYSIS PUMP
EP2120959A4 (en) METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA
HK1213738A1 (zh) 包含 -巰基吡啶- -氧化物和吡咯衍生物的殺生物組合物
SI2097381T1 (sl) 4-(4-((4-kloro-3-(trifluorometil)fenil))karbamoil)amino)-3- fluorofenoksi)-n-metilpiridin-2-karbokasamid monohidrat
EP2332927A4 (en) HETEROCYCLIC COMPOUND CONTAINING NITROGEN AND AGENT FOR CONTROLLING HARMFUL ANIMALS
EP2053021A4 (en) POROUS ORGANOSILICIUM ZEOLITE, ITS PREPARATION AND USE METHOD
IL177366A0 (en) Substituted azetidine compounds as cyclooxygease-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
SG10201501749WA (en) Methods for administering long-lasting hypoglycemic agents
HK1158623A1 (en) Intermediates for the synthesis of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)- ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds 8-[1-(35--())--]-8--17-- [45]-2-
IL212179A0 (en) Nitrogenous heterocyclic compounds, preparation thereof, and use thereof as antibacterial agents
IL201252A0 (en) New nitrogenated heterocyclic compounds, their preparation and use as antibacterial drugs
EP2036909A4 (en) SPIROCYCLOPIPERAZINE QUATERNARY AMMONIUM SALT TYPE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
EP2016504A4 (en) CONSTRUCTION OF A SOCIAL ACTIVITY PROFILE OF A PARTICIPANT IN A COMMUNICATION NETWORK
GB0719592D0 (en) Compound, use and method